EUVIMEDEUVIMED entdecken
Crossref

Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma

Prakash Navaratnam, Eduardo Urdaneta, John McLaughlin, Howard S. Friedman

Health Outcomes Research in Medicine · 2010

DOI: 10.1016/j.ehrm.2010.08.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Outcomes Research in Medicine, 2010. Verfasst von Prakash Navaratnam und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Navaratnam, P., Urdaneta, E., McLaughlin, J., & Friedman, H. S. (2010). Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma. Health Outcomes Research in Medicine. https://doi.org/10.1016/j.ehrm.2010.08.001

Vancouver

Navaratnam P, Urdaneta E, McLaughlin J, Friedman HS. Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma. Health Outcomes Research in Medicine. 2010. doi:10.1016/j.ehrm.2010.08.001

BibTeX
@article{Navaratnam2010,
  author = {Navaratnam, Prakash and Urdaneta, Eduardo and McLaughlin, John and Friedman, Howard S.},
  title = {Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma},
  journal = {Health Outcomes Research in Medicine},
  year = {2010},
  doi = {10.1016/j.ehrm.2010.08.001}
}
Kostenlos starten →